Lawsuit Targets Inovio Pharmaceuticals Over CELLECTRA Manufacturing, INO-3107 BLA Timing

Lawsuit over CELLECTRA manufacturing and INO-3107 BLA timing drives latest action

Rosen Law Firm is reminding purchasers of Inovio Pharmaceuticals securities of a pending class action that centers on alleged misstatements about the company’s manufacturing readiness and regulatory timetable for its INO-3107 vaccine program. The firm says the suit covers transactions from Oct. 10, 2023 through Dec. 26, 2025 and that parties wishing to move for lead plaintiff must do so by April 7, 2026. The complaint alleges Inovio provided materially false or misleading information and omitted facts about deficiencies in manufacturing for its CELLECTRA electroporation device, which the lawsuit contends undermines the company’s ability to support a Biologics License Application (BLA).

Plaintiffs in the complaint focus on two regulatory consequences they say arise from the alleged manufacturing problems: that Inovio is unlikely to submit the INO-3107 BLA to the U.S. Food and Drug Administration in the second half of 2024, and that the company lacks sufficient information to justify eligibility for accelerated approval. The suit frames those issues as central to the development and potential commercialization pathway for INO-3107, a therapeutic candidate Inovio is developing to address human papillomavirus (HPV)-related disease. The complaint asserts that disclosures during the class period downplay or fail to disclose the operational and data shortfalls that would affect BLA timing and regulatory strategy.

The case highlights the intersection of device manufacturing, biologics regulatory requirements and clinical development timelines that biotechnology firms face when seeking licensure. Electroporation devices such as CELLECTRA are integral to DNA medicine delivery, and manufacturing problems could trigger additional data generation and quality controls that delay regulatory filings. The plaintiffs say those downstream impacts are the basis for their claims; Inovio’s public statements and regulatory positioning are therefore central to the litigation going forward.

How investors can respond

Rosen Law is soliciting potential class members and says those who purchased Inovio securities during the class period may pursue recovery through a contingency-fee arrangement without out-of-pocket fees. The firm provides a submission portal, a toll-free number (866-767-3653) and an email ([email protected]) for inquiries and registration.

About the plaintiff counsel

Rosen Law highlights its securities litigation track record, noting past large recoveries and professional recognitions, and cautions investors to select experienced counsel rather than firms that only refer clients. The notice urges prospective plaintiffs to consider counsel credentials when deciding how to participate.